Health ❯ Clinical Trials

Drug Efficacy

Weight Loss Studies Weight Loss Drugs Weight Loss Cardiovascular Health Phase 3 Trials ESSENCE Trial Patient Outcomes Lenacapavir Studies Phase Trials Dosing Strategies FDA Approval Orforglipron Antiretroviral Drugs Regulatory Challenges HIV Research Linzagolix Anti-fibrotic Treatments Toxicity Studies Mounjaro Trials Biomarkers Preventive Treatments Weight Loss Treatments Ruxolitinib Infection Prevention Safety Profile Medical Needs Type 1 Diabetes Treatment Compounded Medications Research Studies Survival Rates Breakthrough Therapy Designation Combination Therapy SERENA-6 Study GLP-1 Therapies Ozempic Trials BCR::ABL1 Inhibitors Medical Results Safety and Tolerability

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

FDA Delays Rivoceranib Approval Citing Manufacturing Compliance at Chinese Plant

Servier to Buy Edgewise Muscular Dystrophy Unit for Up to $2.65 Billion

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Small Molecule Blocks RAGE–DIAPH1 Pathway, Reduces Diabetic Tissue Damage in Mice

South Africa Approves Twice-Yearly HIV Prevention Shot, Clearing Path to 2026 Rollout

Amgen Reports Repatha Cuts First-Event Risk in Primary-Prevention Trial

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement

WHO Endorses Twice-Yearly HIV Prevention Jab as Early Adopters Plan 2026 Rollout